03 July 2023 – TMC provides a full range of expert pharma and biotech support services, from pre-clinical to post-marketing, for human medicines and devices. TMC’s senior team, based in the UK, is supported by a worldwide network of over 900 contracted Associates, who are hand-picked to match the exact needs of each individual project. TMC’s network of Associates includes some of the very best subject-matter experts in medicinal product development.
Expanding into international markets Leading mid-market private equity firm LDC made an £18m minority investment in TMC in 2022, backing the existing management team, led by Co-Founder and CEO Julie Matthews and COO Carol Woodward.
LDC’s minority investment is helping TMC to further expand into the US and Asia markets and support plans to double the number of full-time employees it has over the next five years and open new offices in key international markets. Biotech industry veteran Gordon Cameron joins TMC as a Non-Executive Director.
Milestones reached In 2023, TMC strengthened its team, bringing on board seasoned and talented industry executives as it continues to grow internationally. Successfully attracting these key personnel to TMC is another milestone development in TMC’s growth as it has increased its headcount by >20% since LDC’s investment.
Since partnering with LDC, TMC has also started to increase its international focus with 80% of customers now based in the US.